Citius Oncology (CTOR) AI Stock Analysis

• Market Cap: $91.58M
• Dividend Yield: N/A
• Average Volume (3M): 234.01K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.58
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - General
• EPS (TTM): -0.06
• Shares Outstanding: 84,797,844
• 10 Day Avg. Volume: 272,668
• 30 Day Avg. Volume: 234,012
• PEG Ratio: -0.45
• Price to Book (P/B): 3.32
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -13.23
• Enterprise Value/Market Cap: 1.79
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -6.99
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $1.00 ▼(-6.54% Downside)

The score is primarily weighed down by weak financial performance (pre-revenue, widening losses, and increasing cash burn) and bearish technicals (below key moving averages with negative MACD). Positive corporate events—commercial launch of LYMPHIR and added funding—provide support but do not fully offset profitability and financing risks.

Positive Factors

Commercial Launch

The commercial launch of LYMPHIR marks Citius Oncology's transition to a revenue-generating company, enhancing its market position and potential for sustained growth.

International Expansion

Expanding distribution to international markets increases Citius Oncology's global footprint, potentially boosting revenue and market share in the oncology sector.

Strategic Partnerships

Partnership with EVERSANA provides comprehensive commercialization support, enhancing Citius Oncology's ability to effectively market and distribute LYMPHIR.

Negative Factors

Financial Performance

Pre-revenue status and increasing losses highlight financial instability, raising concerns about the company's ability to sustain operations without additional funding.

Cash Flow Challenges

Negative operating cash flow indicates increasing cash burn, necessitating further capital raises, which could lead to dilution and financial strain.

Equity Erosion

Declining equity due to ongoing losses suggests potential financial instability and increased risk of needing additional capital infusions.

Citius Oncology Business Overview & Revenue Model

Company Description

Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.

How the Company Makes Money

Citius Oncology makes money primarily through the research, development, and commercialization of its cancer treatment drugs. The company's revenue streams include licensing agreements, where it partners with other pharmaceutical companies to co-develop or distribute its products, and sales of approved therapies. Additionally, Citius Oncology may receive milestone payments and royalties from partnerships and collaborations with other entities in the healthcare sector. The company's earnings are influenced by the successful clinical trials and regulatory approval of its drug candidates, as well as strategic partnerships that enhance its market reach.

Citius Oncology Financial Statement Overview

Summary

Citius Oncology's financial performance indicates significant challenges, typical of a pharmaceutical company in development stages. The absence of revenue and consistent net losses highlight a high-risk profile. The balance sheet shows volatility with negative equity in some periods, and cash flow statements reveal liquidity challenges and reliance on financing activities.

Income Statement

Citius Oncology shows a challenging income situation with consistent net losses over the reported periods. The absence of revenue and gross profit highlights the early-stage nature or restructuring phase of the company. Despite some improvement in EBIT from 2023 to 2024, the overall profitability metrics remain weak, given the negative net income.

Balance Sheet

The balance sheet reveals high volatility with fluctuating stockholders' equity and liabilities. Although there is a significant increase in assets from 2023 to 2024, the negative equity in some periods and inconsistent asset base pose stability concerns. The absence of debt could indicate cautious financing, but the negative equity ratios in some periods showcase financial vulnerability.

Cash Flow

Cash flow statements show inconsistent operating cash flows and negative free cash flow, indicating liquidity challenges. The reliance on financing activities to support cash flows is evident, but the lack of consistent positive cash flow from operations could hinder growth prospects. The free cash flow growth rate is negative, which poses a risk for future financial health.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00
EBITDA	-23.49M	-23.49M	-20.57M	-12.12M	-4.86M
Net Income	-24.76M	-24.76M	-21.15M	-12.70M	-5.43M
Balance Sheet
Total Assets	100.94M	100.94M	84.37M	47.73M	42.69M
Cash, Cash Equivalents and Short-Term Investments	3.92M	3.92M	112.00	0.00	0.00
Total Debt	3.80M	3.80M	3.80M	0.00	0.00
Total Liabilities	56.08M	56.08M	38.23M	22.20M	6.42M
Stockholders Equity	44.87M	44.87M	46.14M	25.54M	36.27M
Cash Flow
Free Cash Flow	-5.53M	-11.24M	-4.87M	-601.30K	-47.97K
Operating Cash Flow	-5.53M	-5.49M	126.35K	-601.30K	-47.97K
Investing Cash Flow	-5.79M	-5.75M	-5.00M	-1.32M	-67.32M
Financing Cash Flow	15.29M	15.17M	4.87M	1.66M	67.66M

Citius Oncology Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.07
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTOR, the sentiment is Negative. The current price of 1.07 is below the 20-day moving average (MA) of 1.14, below the 50-day MA of 1.21, and below the 200-day MA of 1.57, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 44.70 is Neutral, neither overbought nor oversold. The STOCH value of 33.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CTOR.

Citius Oncology Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BIIB	74 Outperform	$24.73B	14.99	9.31%	―	5.00%	-1.03%
GRFS	72 Outperform	$7.83B	14.54	6.93%	1.56%	9.45%	167.00%
OGN	53 Neutral	$2.26B	4.52	71.62%	4.80%	-1.69%	-61.89%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CTOR	45 Neutral	$91.58M	-3.11	―	―	―	―
SRXH	41 Neutral	$13.24M	0.07	―	―	-8.12%	―

Citius Oncology Corporate Events

Citius Oncology Raises $18M Through Direct Offering

On December 8, 2025, Citius Oncology entered into a securities purchase agreement with an institutional investor for a registered direct offering and a concurrent private placement, raising approximately $18 million. The proceeds will support the commercial launch of LYMPHIR and general corporate purposes. The offering closed on December 10, 2025, with H.C. Wainwright & Co. acting as the exclusive placement agent. The company also amended existing warrants to reduce exercise prices and adjusted the maturity of a promissory note with Citius Pharmaceuticals.

The most recent analyst rating on (CTOR) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Citius Oncology stock, see the CTOR Stock Forecast page.

Citius Oncology Launches LYMPHIR for Cutaneous T-Cell Lymphoma

On December 1, 2025, Citius Oncology announced the commercial launch of LYMPHIR, a novel IL-2 receptor-directed fusion protein approved by the FDA for treating adult patients with relapsed or refractory Stage I–III cutaneous T-cell lymphoma. This launch marks a significant milestone for the company, enhancing its industry positioning by providing a new treatment option in a competitive landscape and potentially improving patient outcomes.

The most recent analyst rating on (CTOR) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Citius Oncology stock, see the CTOR Stock Forecast page.

Citius Oncology Stockholders Approve Share Increase

On October 27, 2025, Citius Oncology, Inc. held its annual meeting where stockholders approved an amendment to double the shares authorized under the 2024 Omnibus Stock Incentive Plan from 15 million to 30 million, following the Board’s prior approval in September. Additionally, stockholders elected Class I directors Myron Holubiak and Joel Mayersohn for a three-year term and ratified Wolf & Company, P.C. as the independent registered public accounting firm for the fiscal year ending September 30, 2025.

The most recent analyst rating on (CTOR) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Citius Oncology stock, see the CTOR Stock Forecast page.

Citius Oncology Prepares LYMPHIR Launch for Q4 2025

On October 23, 2025, Citius Oncology announced its readiness to launch LYMPHIR in Q4 2025, having invested approximately $90 million in its development and pre-commercial efforts. The company has completed significant pre-commercial activities, including manufacturing inventory, securing supply chain agreements, and developing a marketing strategy. The launch is expected to impact the estimated $400 million addressable U.S. market for CTCL therapies, positioning Citius Oncology as a key player in this niche market.

The most recent analyst rating on (CTOR) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Citius Oncology stock, see the CTOR Stock Forecast page.